Efficacy and safety of fast-acting insulin aspart versus insulin aspart both in combination with insulin degludec with or without metformin in adults with diabetes

被引：0
|
作者：
Du, J. [1 ]
Wang, G. X. [2 ]
Wang, G. [3 ]
Liu, M. [4 ]
Thamattoor, U. K. [5 ]
Luan, Z. J. [6 ]
Alibegovic, A. C. [7 ]
Mu, Y. M. [1 ]
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[2] First Hosp Jilin Univ, Jilin, Jilin, Peoples R China
[3] Beijing Chao Yang Hosp, Beijing, Peoples R China
[4] Tianjin Med Univ Gen Hosp, Tianjin, Peoples R China
[5] Novo Nordisk India Private Ltd, Global Business Serv, Bangalore, Karnataka, India
[6] Novo Nordisk, Beijing, Peoples R China
[7] Novo Nordisk AS, Soborg, Denmark
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
739
引用
收藏
页码：S377 / S377
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Niu, Yan-Li
    Zhang, Ye
    Song, Zhi-Yong
    Zhao, Chuan-Zhi
    Luo, Yun
    Wang, Yan
    Yuan, Jing
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2024, 53 (02) : 313 - 322
  • [32] Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus
    Gillian M. Keating
    Drugs, 2013, 73 : 575 - 593
  • [33] Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial
    Battelino, Tadej
    Deeb, Larry C.
    Ekelund, Magnus
    Kinduryte, Ona
    Klingensmith, Georgeanna J.
    Kocova, Mirjana
    Kovarenko, Margarita
    Shehadeh, Naim
    PEDIATRIC DIABETES, 2018, 19 (07) : 1263 - 1270
  • [34] Hypoglycemia with Mealtime Fast-Acting Insulin Aspart vs. Insulin Aspart Across Two Large Type 1 Diabetes Trials
    De Block, Christophe
    Carlson, Anders
    Rose, Ludger
    Gondolf, Theis
    Gorst-Rasmussen, Anders
    Lane, Wendy
    DIABETES, 2018, 67
  • [35] Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
    Luo, Qiong
    Zhou, Li
    Zhou, Naitong
    Hu, Ming
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [36] Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus
    Keating, Gillian M.
    DRUGS, 2013, 73 (06) : 575 - 593
  • [37] Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes
    Oya, Junko
    Nakagami, Tomoko
    Hasegawa, Yukiko
    Kondo, Yuichiro
    Katamine, Aki
    Shimizu, Mika
    Kubota, Ryo
    Suda, Rika
    Babazono, Tetsuya
    DIABETOLOGY INTERNATIONAL, 2024, 15 (02) : 237 - 243
  • [38] Improved glycaemic control with carbohydrate counting for adjustment of fast-acting insulin aspart vs insulin aspart in subjects with Type 1 diabetes
    Leelarathna, L.
    Philis-Tsimikas, A.
    Bode, B. W.
    Franek, E.
    Rose, L.
    Buchholtz, K.
    Pieber, T. R.
    DIABETIC MEDICINE, 2018, 35 : 19 - 19
  • [39] Efficacy and safety of a combination of miglitol, metformin and insulin aspart in the treatment of type 2 diabetes
    Ke, Tingyu
    Cheng, Guoliang
    Tan, Liping
    Zhou, Xiangming
    Miao, Yuanyuan
    Du, Shigang
    Wang, Jia
    Pan, Yi
    Bi, Jingjie
    Zhao, Lin
    Zhi, Yunxia
    Zhao, Ling
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2021, 20 (10) : 2171 - 2177
  • [40] Efficacy and Safety of Insulin Aspart 30 and Insulin Degludec/Aspart vs. Basal Insulin in Patients with Type 2 Diabetes: A Meta-analysis
    Mishriky, Basem M.
    Tanenberg, Robert J.
    Cummings, Doyle M.
    DIABETES, 2017, 66 : A252 - A252
12345